MedTrace Logo

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-11-18

Study results available
· View outcomes & findings →

Summary

This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

Conditions

Interventions

DRUG

KZR-616

Subcutaneous Injection of KZR-616

Sponsors & Collaborators

  • Kezar Life Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Kezar · Kezar Life Sciences, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2022-08-04
Completion
2022-08-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Colombia
  • Mexico
  • Peru
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393013 on ClinicalTrials.gov